Investigating bleeding issues related to heart support devices
Von Willebrand Factor Hyperactivity, Angiogenesis and LVAD-Induced Bleeding
['FUNDING_R01'] · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · NIH-11080772
This study is looking at why some patients with advanced heart disease who use heart pumps (LVADs) have problems with bleeding, and it hopes to find ways to help these patients feel better and stay healthier.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-11080772 on ClinicalTrials.gov |
What this research studies
This research focuses on patients with end-stage heart disease who use left ventricular assist devices (LVADs) to support their heart function. It aims to understand why some patients experience significant bleeding complications, known as acquired von Willebrand syndrome, despite advancements in LVAD technology. The study will analyze the behavior of von Willebrand factor (VWF) in these patients, particularly how high shear stress from the device affects VWF cleavage and activation. By examining these mechanisms, the research seeks to identify the underlying causes of bleeding and improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with end-stage heart disease who are currently using or are candidates for left ventricular assist devices.
Not a fit: Patients who do not have end-stage heart disease or those who are not using LVADs may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better management of bleeding complications in patients using LVADs, ultimately improving their survival and quality of life.
How similar studies have performed: Previous research has shown that understanding the mechanisms of bleeding in patients with LVADs can lead to significant improvements in patient care, indicating that this approach has potential for success.
Where this research is happening
HOUSTON, UNITED STATES
- UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: NASCIMBENE, ANGELO — UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
- Study coordinator: NASCIMBENE, ANGELO
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired von Willebrand disease, Acquired Von Willebrand syndrome